Email

niaid.nih.gov> Cc: Glass, Roger (NIH/FIC) [E] mail.nih.gov>; Eiss, Robert (NIH/FIC) [E] mail.nih.gov>; Kilmarx, Peter (NIH/FIC) [E] nih.gov>; Wolinetz, Carrie (NIH/OD) [E] nih.gov>; Lauer, Michael (NIH/OD) nih.gov>; Garbarini, Nicole (NIH/OD) [E] nih.gov>; Johnson, Martin S. (NIH/NIAID) niaid.nih.gov>; McGowan, John J. (NIH/NIAID) [E] niaid.nih.gov>; Schwetz, Tara (NIH/NIAID) [€] [FO nih.gov> Subject: Re: Need info on BMGF -- Urgent Many thanks From: Anthony Fauci HE viaid.nih.gov> Date: Friday, May 25, 2018 at 8:07 PM nih.gov> mail.nih.gov>, "Eiss, Robert (NIH/FIC) [E]" Hie mail nih.gov>, nih.gov>, "Wolinetz, Carrie (NIH/OD) [E]" HR nih.cov>, "Lauer, Michael (NIH/OD) [E]" I h.gov>, "Garbarini, Nicole |AID) (E]" >, P| \IH/NIAID) [E]" -- Urgent ng be P| > wrote: (NIH/OD) [E]" @nih.gov>, "Johnson, Martin S. (NIH/NIAID) [E]" @niaid.nih.gov>, "McGowan, John J. (NIH/NIAID) [E]" @niaid.nih.gov>, "Schwetz, Tara (NIH/NIAID) [E]" @nih.gov> Subject: Re: Need info on BMGF -- Urgent Larry: BMGF is co-funding with NIAID the Cabotegravir PrEP study. I do not know how much they are in for. Also, Bob Seder of the VRC heavily advises and consults for the BMGF; however, no $ is involved . Everything else that you have listed is correct. Tony On May 25, 2018, at 6:29 PM, Tabak, Lawrence (NIH/OD) [E] @nih.gov> wrote: Dropping FC off. Could you all please do a quick check to make sure I haven't included anything that is wrong. I would like to get this to FC either late tonight or first thing in the AM before I get on a plane. With thanks to Mike and Nicole, here is what we have found thus far: 1. We found nothing in which the BMGF is the primary recipient of NIH funds - they are not in our organization list meaning they have never been an applicant for grant money from NIH. I don't know anything about contracts. 2. The first attachment displays projects with co-funding- NIH $ are displayed - that is NOT going to BMGF, it is going to the listed investigator 3. BMGF has funded various components of NIH (through the Grand Challenges Program, although that may not be the only program) - I have only listed funding from 2018-2015; there are earlier grants NIAID: https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2018/02/OPP1162695 https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/11/OPP1178956 https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/02/OPP1159915 https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/11/OPP1139518 FIC: https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/07/OPP1169078 https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/09/OPP1129994 NHLBI: https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/08/OPP1131279 NICHD: https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/05/OPP1129091 larry -- On 5/25/18, 4:55 PM, "Collins, Francis (NIH/OD) [E]" @od.nih.gov> wrote: For reasons I can't currently explain, I need answers to the following: 1) are we giving any grants to BMGF (I assume no) FC ne 2) what are our current collaborative projects with BMGF? For each one , what is the rough NIH annual spend, and what is it from BMGF? Hoping this won't be too hard to dig out. Ideally I need a response (at least a rough version) by Saturday 4 pm. Questions? Call Getting on a plane in 10 minutes FC Sent from my iPhone <SR_25May2018_053723_24581657[3].xlsx> Select Recent Highlights NIH-Bill & Melinda Gates Foundation Cooperation • Efficacy studies of two HIV vaccines moving forward o The P5 vaccine efficacy study (HVTN 702), which launched in November 2016 in South Africa, is the first HIV vaccine efficacy study in 7 years o The Imbokodo (HVTN 705) study, which launched in November 2017, is a Phase 2b proof-of-concept study evaluating the safety and efficacy of a Ad26 mosaic vaccine and Clade C gp140. The vaccine regimen is based on "mosaic" immunogens -- vaccine components designed to induce immune responses against a wide variety of global HIV strains. • Evaluation of a novel, long acting injectable antiviral for HIV Prevention o In November 2017, launched Phase III efficacy study (HPTN 084) to compare long-acting cabotegravir to daily Truvada for pre-exposure prophylaxis in HIV-uninfected women. • TB Drug development and clinical endpoints o NIAID intramural collaborations with BMGF have contributed to novel clinical markers for treatment response (PET/CT, NexGenNCT02371681) that are now further evaluated in the "PREDICT TB" trial (NCT02821832) to identify patients who may benefit from shortened therapy. o